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Abstract We report on epidemiology, features, outcome,
and domiciliary management of pain in patients with
advanced hematological malignancies followed by an
experienced hospital-based home care (HC) team. Out of
469 patients, 244 (52%) experienced a total of 284 pain
syndromes. Pain intensity was rated from mild to moderate
in 31% and from moderate to severe in 69% of them. The
diagnosed pain mechanisms were deep somatic in 56%,
superficial somatic in 15%, visceral 14%, mixed 8%, and
neuropathic in 7% of pain syndromes, respectively. Incident
pain was observed in 38% of all pain syndromes. In every
diagnostic group, deep somatic pain was prevalent. More-
over, 85% of visceral pain syndromes were observed in
patients affected by non-Hodgkin’s lymphoma (NHL). In
addition, out of 284 pain syndromes, 150 (51%) were
caused by bone involvement. The most frequent recognized
pain provocative mechanisms were bone marrow expan-
sions, osteolysis, lymph node enlargement, and mucositis.
In our experience, an approach based on the association of
causal therapies and analgesics allows optimal control of
most pain syndromes. Therefore, pain is a major problem in
patients affected by advanced hematological malignancies,
and its management can be effective and feasible when
carried out by a skilled HC team.
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Introduction
So far, pain epidemiology in patients with advanced hema-
tological malignancies, other than multiple myeloma (MM),
has been poorly investigated (Table 1). This symptom has
traditionally been believed to be a rare manifestation
compared to solid tumor settings [1–3]. Nevertheless, more
recent studies have shown a high prevalence of this
symptom in the hematological population [4–7], in which
the occurrence of specific pain syndromes has been
described [8]. However, no study on this topic concerning
patients with blood-related neoplasm in the home care (HC)
setting has been reported. To address this issue, we
conducted a 6-year prospective study on the domiciliary
management of a cohort of patients with advanced blood-
related neoplasm followed at home by a hospital-based
multidisciplinary HC team [9, 10].
Materials and methods
The study included 469 patients followed at home over a
6-year period by a team composed of seven hematologists,
ten nurses, two psychologists, one social worker, and
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several other care providers trained in palliative care. A
physician and a nurse were available on duty 24 h a day all
year round. The HC process was based on specific internal
operating models and team guidelines to ensure continuous
efforts toward the best quality of care [10]. The decision to
follow a patient at home was taken together by the referral
hematologist and HC team. The availability at home of a
reliable and educated caregiver has been considered an
essential condition to activate a HC program. Regular
weekly team meetings allowed the examination of
emerging problems and to refine treatment and care
objectives. The HC team worked together with the general
services and diagnostic structures of the Human Biopathol-
ogy and Haematology Department, “La Sapienza” Univer-
sity, Rome. In addition, a close collaboration with a hospice
guaranteed periodical family relief and the palliation of
specific refractory symptoms requiring measures unavailable
at home.
From the assessment up to the end-life care, precise
decisions have been implemented and applied [10], in
particular regarding pain therapy, transfusion policy, infec-
tion treatments, and bleeding management in all phases of
HC processes.
Pain, as the fifth vital sign, was assessed, during a
clinical visit, every 24 h until analgesia and then every
3 days. The pain intensity was reported by a Numerical
Analogue Scale (NRS), which rated 0 (no pain), 1 to 3
(mild pain), 4 to 6 (moderate), and 7 to 10 (severe). In less
reliable patients, only a verbal description scale including
four items: “no pain,” “mild pain,” “moderate,” and “severe
pain” [11] was applied. In nonverbal patients, like young
children and some cognitive-impaired elderly, a face pain
scale [12] and, in very few cases, the parent ratings (four
items as above) as proxy measures [13] were adopted. Each
pain syndrome was properly assessed and classified by the
treating physicians as deep somatic, superficial somatic,
Table 2 Patient’s demographic features, incidence, and distribution of pain syndromes according to the diagnosis
Malignancy Patients M/F Mean Age (SD) Incidence of pain Pain syndromes
No. Percent No. Years Percent No.
NHL 128 27 71/57 61 (17) 60 89
AML 69 15 38/31 63 (20) 41 34
MDS 63 13 32/31 78 (7) 32 22
BC 56 12 30/26 61 (15) 52 34
ALL 39 8 23/16 29 (21) 79 40
MM 39 8 19/20 71 (9) 90 38
CMPD 33 7 22/11 78 (9) 18 8
CLL 24 5 13/11 73 (8) 42 11
HD 11 3 6/5 50 (27) 45 5
Others 7 2 4/3 66 (16) 43 3
Total 469 100 258/211 63 (20) 52 284
MM Multiple myeloma, ALL acute lymphoblastic leukemia, NHL non-Hodgkin’s lymphomas; BC blastic crisis, HD Hodgkin’s disease, CLL
chronic lymphocytic leukemia, acute myeloblastic leukemia, MDS myelodysplastic syndromes, CMPD chronic myeloproliferative disorders
Table 1 Pathophysiology of the most common pain syndromes in patients with hematological malignancies
Pain type Pain origin and syndromes
Nociceptive Deep somatic Bone marrow expansion and osteolysis. Spleen and liver capsulae distension by tumor infiltration and
organ enlargement. Headache by liquor loss (post dural puncture); intracranial hypertension
(meningeal and/or brain tumor involvement)
Superficial somatic Mucositis, cutaneous lesions
Visceral Infiltration and/or compression of viscera cava by abdominal nodes, spleen, and liver enlargement
Neuropathic Peripheral neuropathic Vinca alkaloids, thalidomide and bortezomib toxicity. Post-herpetic neuralgia. Neuropathies due to
para-proteins. Amyloidosys. Plexopathy by tumor invasion and/or node enlargement compression
(lymphomas)
Central Neuropathic CNS damage and/or tumor involvement
Mixed Neuropathic + somatic Meningosis, peripheral nerve damage, and/or tumor involvement
Breakthrough Incident (related to the
movement)
Osteolysis, mucositis, cutaneous derangement
Non incident pain Transient pain flares during stable analgesia
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visceral, neuropathic, and mixed or unknown [14, 15].
Incidental pain development, which was related to move-
ments, was also assessed.
A treatment protocol based on the World Health
Organization analgesic ladder [16] and according to the
principles of opioid management for onco-hematological
patients [17] was applied in association with causal mea-
sures if required. Patients whose pain was considered mild
were treated with acetaminophen (if thrombocytopenic) or
nonsteroidal anti-inflammatory drugs; for moderate pain,
weak opioids were used; strong opioids were administered
to manage severe pain. Adjuvant drugs were added ac-
cording to the neuropathic features of pain for each step. No
devices were implanted.
Pain control was defined by almost 50% reduction in
pain intensity compared to baseline and to a NRS<5. The
data were collected, and a computer-based statistical anal-
ysis was performed. The parametric and nonparametric
variables were analyzed by the Student’s t test and the chi-
square test, respectively. p values<0.05 were considered
statistically significant.
Results
Diagnoses are shown in Table 2. There were 258 (55%)
men, with a median age of 67 (4–95) years; the median
Karnofsky performance status (KPS) was 50 (10–70).
Patients were properly informed about the aims of the
study and gave their consent.
They were followed at home for a mean of 72±144
(range 1–1,132) days; 368 (85%) patients died at home and
65 (15%) after a hospital admission. Out of 469 patients,
244 (52%) experienced almost one pain syndrome, for a total
of 284, the intensity of which was rated frommild to moderate
in 92 (31%) and from moderate to severe in 192 (69%).
Patients who experienced pain were significantly youn-
ger than those without pain (57±21 vs 69±16, p<0.0005).
Moreover, a significantly higher incidence of pain was
recorded, in 49 patients younger than 20, compared to
others (85% vs 49%, p=0.0007).
Patients affected by MM, acute lymphoblastic leukemia
(ALL), NHL, and blastic crisis (BC) had a higher incidence
of pain compared to other disease groups (p=0.0011).
Table 3 Neurophysiological classification of pain syndromes and their distribution according to the diagnosis
Pain Malignancy
No. (%)
MM ALL NHL BC HD CLL AML CMPD MDS Oth Total
DS 30 (80) 20 (50) 35 (39) 20 (59) 5 (100) 18 (57) 10 (77) 12 (60) 6 (60) 3 (100) 159 (56)
SS 3 (8) 8 (20) 10 (11) 6 (17) 0 7 (22) 2 (15) 5 (25) 1 (10) 0 42 (15)
Vis 1 (2) 0 33 (37) 0 0 1 (3) 1 (8) 1 (5) 2 (20) 0 39 (14)
NP 1 (2) 5 (12) 4 (5) 4 (12) 0 4 (12) 0 1 (5) 1 (10) 0 20 (7)
Mix 3 (8) 7 (18) 7 (8) 4 (12) 0 2 (6) 0 1 (5) 0 0 24 (8)
Total 38 (100) 40 (100) 89 (100) 34 (100) 5 (100) 32 (100) 13 (100) 20 (100) 10 (100) 3 (100) 284 (100)
DS Deep somatic, SS superficial somatic, Vis visceral, NP neuropathic pain, Mix mixed
Table 4 Pathogenetic mecha-
nisms and their distribution
according to neurophysiologi-
cal classification
DS Deep somatic; SS superfi-
cial somatic; Visc visceral; NP
neuropathic; BM bone marrow;
ZP zoster pain; PHN post-
herpetic neuralgia
Cause Kind of pain t4.1
DS SS Visc NP Mixed Total t4.2
No. (%) t4.3
BM expansion 80 (50) 0 0 0 13 (54) 93 (33) t4.4
Osteolysis 44 (27) 0 0 0 2 (9) 46 (16) t4.5
Lymphoadenomegaly 0 0 33 (85) 0 3 (12) 36 (13) t4.6
Mucositis 0 31 (74) 0 0 0 31 (11) t4.7
ZP and PHN 0 0 0 18 (90) 0 18 (6) t4.8
Organ enlargements 14 (9) 0 0 0 0 14 (5) t4.9
Meningosis 8 (5) 0 0 0 5 (21) 13 (5) t4.10
Cutaneous ulcers 0 11 (26) 0 0 0 11 (4) t4.11
Infections 7 (5) 0 0 0 0 7 (2) t4.12
Neuropathies 0 0 0 2 (10) 0 2 (0.7) t4.13
Others 6 (4) 0 6 (15) 0 1 (4) 12 (4.3) t4.14
Total 159 (100) 42 (100) 39 (100) 20 (100) 24 (100) 284 (100) t4.15
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Among patients with acute leukemias, ALL patients had a
higher incidence of pain compared to myeloblastic subtypes
(79% vs 41%, p=0.0002; Table 2).
Pain syndromes were diagnosed as deep somatic (56%),
superficial somatic (15%), visceral (14%), neuropathic (7%),
and mixed (8%). In all diagnosis groups, a higher incidence
of deep somatic pain has been recorded (Table 3). Moreover,
out of 39 visceral pain states, 33 (85%) have been observed
in NHL patients and 6 (15%) in others ( p=0.0001).
The occurrence of incidental pain, including pure and
mixed incidental (continuous nociceptive plus incidental
pain), was recorded in 106/284 (38%) of pain syndromes
with a higher rate in MM patients, in which this pain
feature was recorded in 32 (85%) out of 38 of pain syn-
dromes. The causative mechanisms of pain were directly
referable to underlying diseases, to their clinical complica-
tions, or other unrelated conditions in 69, 22, and 9% of
pain syndromes, respectively (Tables 4 and 5). The most
involved sites and the percentages of the respectively
afflicting pain syndromes (Table 6) were as follows: spine
(27%), abdomen (20%), legs (15%), thorax (11%), oro-
faringeal tract (10%), diffuse (7%), and others (10%).
No significant differences were found in the length of
HC stay results between patients suffering from pain
compared to others (67 vs 76 days, p=0.46).
The pain management was entirely provided at home,
given that no truly intractable pain requiring hospital
admission was observed. Although an effective pain control
was attained in 259/284 (92%) of pain syndromes, a
completely stable pain relief was achieved in 202/284
(71%) of them. A lower response rate was found in the
presence of neuropathic and incidental features (Table 7).
Indeed, in the group of patients presenting these poor
prognostic features compared to those with only continuous
nociceptive pain, a completely stable pain relief was
attained in 69/150 (46%) vs 132/135 (98%; p=0.0001).
Discussion
Our data indicate that pain is a major concern for patients
suffering from advanced hematological malignancies;
therefore, its management should be one of the most
important aspects of a domiciliary palliative care program
[18]. Moreover, according to the type of underlying
malignancy and to the pattern of the disease involvement,
different painful syndromes, sometimes overlapping, may
be distinguished [7]. Two main pain types can be dis-




Lower extremities 43 15
Thorax 31 11
Orofaringeal cable 31 10
Diffuse 20 7
Head and facial bone 20 7
Pelvis bones 5 2
Cervical region 2 1
Total 284 100
Table 5 Pathogenetic mecha-
nisms of pain
CN Continuous nociceptive;
MI mixed incident; PI pure
incident; NP neuropathic
Causes Pain t5.1
CN MI PI NP Mixed Total t5.2
No. (%) t5.3
BM expansion 70 (52) 10 (10) 0 0 13 (54) 93 (33) t5.4
Osteolysis 0 41 (41) 3 (60) 0 2 (9) 46 (16) t5.5
Lymphoadenomegaly 33 (25) 0 0 0 3 (12) 36 (13) t5.6
Mucositis 0 31 (31) 0 0 0 31 (11) t5.7
ZP and PHN 0 0 0 18 (90) 0 18 (6) t5.8
Organ enlargements 14 (10) 0 0 0 0 14 (5) t5.9
Meningosis 8 (6) 0 0 0 5 (21) 13 (5) t5.10
Cutaneous ulcers 0 11 (10) 0 0 0 11 (4) t5.11
Infections 3 (2) 4 (4) 0 0 0 7 (2) t5.12
Neuropathies 0 0 0 2 (10) 0 2 (0.7) t5.13
Others 6 (5) 4 (4) 2 (40) 0 1 (4) 5 (4.3) t5.14
Total 134 (100) 101 (100) 5 (100) 20 (100) 24 (100) 284 (100) t5.15








132 (98) 42 (40) 27 (61) 202 (71)
Poor (%) 2 (2) 64 (60) 17 (29) 82 (29)
Total (%) 134 (100) 106 (100) 44 (100) 284 (100)
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tinguished, based on the causative mechanisms: nociceptive
(somatic and visceral) pain, mediated by the activation of
normal nerve endings, and neuropathic pain caused by
injuries to the peripheral or central nervous system. The
main issue in differentiating neuropathic from nociceptive
pain is to determine appropriate pharmacological manage-
ment, given that most neuropathic pains may require high
doses of opioids and the addition of an adjuvant analgesic
regime (antidepressant or anticonvulsant drugs) [17].
The occurrence of incidental pain, which is a severe
movement-induced transient pain flare, should be evaluated
in the assessment of each pain syndrome, although the
patient may be relatively comfortable at rest. This kind of
pain, in our experience, afflicted most of the patients with
skeletal damages and those presenting mucositis and skin
ulcers. It has been described as a heterogeneous phenom-
enon, which may be a marker for more severe pain syn-
dromes, being associated with functional impairment,
psychological distress, and poor pain control [7, 14, 19].
Regarding the provocative mechanisms, skeletal lesions
afflicted most MM patients, who suffered from localized
and sometimes irradiated nociceptive continuous pain at
rest, complicated by neuropathic symptoms (mixed pain)
and incidental pain.
Node enlargement, visceral localizations, and spleen and
liver capsulae distension are typically recorded in NHL
patients and, to a minor extent, in those affected by other
chronic lympho-proliferative disorders and chronic myelo-
proliferative malignancies. The meningeal and/or brain
localization, mainly recorded in ALL patients, causes, in
most cases, diffuse headache due to stretching and com-
pression of the meninges, intracranial veins, and meningeal
arteries (deep somatic pain), or to the tumor growth around
cranial nerves (neuropathic pain). In our series, the overall
incidence of pain was 52%, with higher values recorded in
patients affected by MM, ALL, NHL, and BC. Among 258
patients experiencing pain, 35 (14%) presented more than
one pain syndrome, underlining that pain states related to
hematological malignancies may be due to very heteroge-
neous and sometimes coexisting mechanisms. Skeletal
damage and/or bone marrow (BM) involvement are char-
acteristics of these diseases, and as expected, the incidence
of deep somatic pain was higher among patients with MM,
ALL, BC, and acute myeloid leukemia (AML). However,
the sites of pain were uniformly distributed; spine and
abdomen were the most afflicted anatomical regions.
Even in the hematological setting, pain can become a
compelling clinical problem. Indeed, we found that 150/284
(53%) of all diagnosed pain syndromes were complicated
by poor prognostic factors, such as neuropathic and
incidental pain features, associated with poor pain control
by opioids [20]. Moreover the pain intensity was rated as 5
or above (moderate to severe pain) in 69%, and those
values are considered substantial and interfering with the
quality of life [11]. Although the study has not been
designed to address the treatment of pain in HC, we found
that a comprehensive approach based on a multidisciplinary
and structured HC service and on standardized protocols
was feasible and allowed for acceptable pain relief at home
in more than 90% of pain syndromes, included those
having poor prognosis. In conclusion, in the setting of
advanced hematological patients referred to a HC program,
pain represents a challenging concern for which domiciliary
management can be a feasible and effective solution when
carried out by a skilled HC team.
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